Iron-replacement therapy delivered via dialysate

Class

Iron-replacement therapy delivered via dialysate — ferric pyrophosphate donates iron directly to circulating transferrin (bypassing the reticuloendothelial macrophage iron-storage step used by IV iron), for use during hemodialysis

Pathway

Iron repletion / erythropoiesis substrate supply

Notes

original target text: Iron-replacement therapy delivered via dialysate — ferric pyrophosphate donates iron directly to circulating transferrin (bypassing the reticuloendothelial macrophage iron-storage step used by IV iron), for use during hemodialysis

Patients undergoing hemodialysis frequently develop iron-deficiency anemia because of chronic blood loss during treatment, reduced dietary intake, and impaired iron absorption. Adequate iron is a required substrate for erythropoiesis, the production of red blood cells, and is especially important in patients also receiving erythropoiesis-stimulating agents, which increase red cell production and thereby increase iron demand. Conventional intravenous iron formulations are taken up by macrophages of the reticuloendothelial system, stored as ferritin, and must later be released and loaded onto the plasma iron-transport protein transferrin before it can reach developing red blood cells. This mechanism instead delivers a soluble iron complex, ferric pyrophosphate, through the dialysate solution during a hemodialysis session, allowing iron to bind transferrin directly in the bloodstream without first passing through macrophage storage. This bypass is intended to provide a steady, low-dose supply of iron matched to the ongoing losses of dialysis, avoiding the storage-and-release step that can be slowed by inflammatory signaling. This approach is relevant broadly to renal anemia management and to any setting where impaired mobilization of stored iron limits the effectiveness of erythropoiesis-stimulating therapy.